G R de Jesús1, S Sciascia2, D Andrade3, M Barbhaiya4, M Tektonidou5, A Banzato6, V Pengo6, L Ji7, P L Meroni8, A Ugarte9, H Cohen10, D W Branch11, L Andreoli12, H M Belmont13, P R Fortin14, M Petri15, E Rodriguez16, R Cervera17, J S Knight18, T Atsumi19, R Willis20, I S Nascimento3, R Rosa3, D Erkan4, R A Levy21,22. 1. Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. 2. Department of Clinical and Biological Sciences, Centre of Research of Immunopathology and Rare Diseases, University of Turin, Turin, Italy. 3. Departament of Rheumatology, Universidade de São Paulo, São Paulo, Brazil. 4. Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA. 5. Rheumatology Unit, First Department of Propaedeutic Internal Medicine, University of Athens, Athens, Greece. 6. Department of Cardiac, Thoracic, and Vascular Sciences, University of Padova, Padova, Italy. 7. Rheumatology and Immunology Department, Peking University, First Hospital, Beijing, China. 8. Department of Rheumatology, University of Milan, Milan, Italy. 9. Autoimmune Diseases Research Unit, Department of Internal Medicine, Hospital Universitario Cruces, Barakaldo, Spain. 10. Department of Haematology, University College London, London, UK. 11. Department of Obstetrics and Gynecology, University of Utah Health Sciences and Intermountain Healthcare, Salt Lake City, UT, USA. 12. Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 13. Division of Rheumatology, NYU School of Medicine, New York, NY, USA. 14. Division of Rheumatology, Centre Hospitalier de l'Université Laval, Québec, QC, Canada. 15. Division of Rheumatology, John Hopkins University, Baltimore, MD, USA. 16. Rheumatology Department, Hospital 12 de Octubre, Madrid, Spain. 17. Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain. 18. Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA. 19. Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 20. Antiphospholipid Standardization Laboratory, Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA. 21. Department of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. 22. GlaxoSmithKline Immunology and Inflammation, Upper Providence, PA, USA.
Abstract
OBJECTIVE: To evaluate the subsequent rate of thrombosis among women with obstetric antiphospholipid syndrome (Ob-APS) in a multicentre database of antiphospholipid antibody (aPL)-positive patients, and the clinical utility of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS), a validated tool to assess the likelihood of developing new thrombosis, in this group of patients. DESIGN: Retrospective study. SETTING: The Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository. POPULATION: Women with Ob-APS. METHODS: Comparison of clinical and laboratory characteristics and measurement of aGAPSS in women with Ob-APS, with or without thrombosis, after initial pregnancy morbidity (PM). MAIN OUTCOME MEASURES: Risk factors for thrombosis and aGAPSS. RESULTS: Of 550 patients, 126 had Ob-APS; 74/126 (59%) presented with thrombosis, and 47 (63%) of these women developed thrombosis after initial PM, in a mean time of 7.6 ± 8.2 years (4.9/100 patient years). Younger age at diagnosis of Ob-APS, additional cardiovascular risk factors, superficial vein thrombosis, heart valve disease, and multiple aPL positivity increased the risk of first thrombosis after PM. Women with thrombosis after PM had a higher aGAPSS compared with women with Ob-APS alone [median 11.5 (4-16) versus 9 (4-13); P = 0.0089]. CONCLUSION: Based on a retrospective analysis of our multicentre aPL database, 63% of women with Ob-APS developed thrombosis after initial obstetric morbidity; additional thrombosis risk factors, selected clinical manifestations, and high-risk aPL profile increased the risk. Women with subsequent thrombosis after Ob-APS had a higher aGAPSS at entry to the registry. We believe that aGAPSS is a valid tool to improve risk stratification in aPL-positive women. TWEETABLE ABSTRACT: More than 60% of women with obstetric antiphospholipid syndrome had thrombosis after initial pregnancy morbidity.
OBJECTIVE: To evaluate the subsequent rate of thrombosis among women with obstetric antiphospholipid syndrome (Ob-APS) in a multicentre database of antiphospholipid antibody (aPL)-positive patients, and the clinical utility of the adjusted Global Antiphospholipid Syndrome Score (aGAPSS), a validated tool to assess the likelihood of developing new thrombosis, in this group of patients. DESIGN: Retrospective study. SETTING: The Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository. POPULATION: Women with Ob-APS. METHODS: Comparison of clinical and laboratory characteristics and measurement of aGAPSS in women with Ob-APS, with or without thrombosis, after initial pregnancy morbidity (PM). MAIN OUTCOME MEASURES: Risk factors for thrombosis and aGAPSS. RESULTS: Of 550 patients, 126 had Ob-APS; 74/126 (59%) presented with thrombosis, and 47 (63%) of these women developed thrombosis after initial PM, in a mean time of 7.6 ± 8.2 years (4.9/100 patient years). Younger age at diagnosis of Ob-APS, additional cardiovascular risk factors, superficial vein thrombosis, heart valve disease, and multiple aPL positivity increased the risk of first thrombosis after PM. Women with thrombosis after PM had a higher aGAPSS compared with women with Ob-APS alone [median 11.5 (4-16) versus 9 (4-13); P = 0.0089]. CONCLUSION: Based on a retrospective analysis of our multicentre aPL database, 63% of women with Ob-APS developed thrombosis after initial obstetric morbidity; additional thrombosis risk factors, selected clinical manifestations, and high-risk aPL profile increased the risk. Women with subsequent thrombosis after Ob-APS had a higher aGAPSS at entry to the registry. We believe that aGAPSS is a valid tool to improve risk stratification in aPL-positive women. TWEETABLE ABSTRACT: More than 60% of women with obstetric antiphospholipid syndrome had thrombosis after initial pregnancy morbidity.
Authors: S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis Journal: J Thromb Haemost Date: 2006-02 Impact factor: 5.824
Authors: Maria Angeles Martinez-Zamora; Sara Peralta; Montserrat Creus; Dolors Tassies; Juan Carlos Reverter; Gerard Espinosa; Ricard Cervera; Francisco Carmona; Juan Balasch Journal: Ann Rheum Dis Date: 2011-09-06 Impact factor: 19.103
Authors: M Radin; K Schreiber; P Costanzo; I Cecchi; D Roccatello; S Baldovino; M Bazzan; M J Cuadrado; S Sciascia Journal: Int J Cardiol Date: 2017-03-24 Impact factor: 4.164
Authors: G Lefèvre; M Lambert; J-L Bacri; S Dubucquoi; T Quemeneur; C Caron; D Launay; V Houfflin-Debarge; E Hachulla; X Kyndt; D Subtil; P-Y Hatron Journal: Lupus Date: 2011-05-05 Impact factor: 2.911
Authors: Savino Sciascia; Maria Jose Cuadrado; Giovanni Sanna; Veronica Murru; Dario Roccatello; Munther A Khamashta; Maria Laura Bertolaccini Journal: Arthritis Care Res (Hoboken) Date: 2014-12 Impact factor: 4.794
Authors: Gautam Sule; William J Kelley; Kelsey Gockman; Srilakshmi Yalavarthi; Andrew P Vreede; Alison L Banka; Paula L Bockenstedt; Omolola Eniola-Adefeso; Jason S Knight Journal: Arthritis Rheumatol Date: 2020-01 Impact factor: 10.995